SciELO - Scientific Electronic Library Online

vol.22 issue4Post-infection sequelae of COVID 19 among patients of Hospital I Florencia de Mora. Trujillo - PeruLimited Periauricular Facelift How to deal with short scar: A technical contribution author indexsubject indexarticles search
Home Pagealphabetic serial listing  

Services on Demand




  • Have no cited articlesCited by SciELO

Related links

  • Have no similar articlesSimilars in SciELO


Revista de la Facultad de Medicina Humana

Print version ISSN 1814-5469On-line version ISSN 2308-0531

Rev. Fac. Med. Hum. vol.22 no.4 Lima Oct./Dec. 2022  Epub Oct 12, 2022 

Original article

Clinical-epidemiological and treatment characteristics of children with COVID-19 in a tertiary referral center in Peru

Christian Chiara Chilet1 

Medalit Luna Vilchez1 

Julio Maquera-Afaray1  2 

Blanca Salazar Mesones1 

Diana Portillo Alvarez1 

Ramiro Priale Miranda1 

Franklin Mendoza1 

Aldo Munayco1 

Mitsi Santiago3 

Jose W. López1  4 

1Unidad de Atención Integral Especializada, Instituto Nacional de Salud del Niño San Borja, Lima, Perú.

2Facultad de Ciencias de la Salud, Universidad Privada de Tacna, Tacna, Perú

3Coordinación técnica de epidemiología, Instituto Nacional de Salud del Niño San Borja, Lima, Perú.

4Facultad de Ciencias de la Salud, Universidad Científica del Sur, Lima, Perú.



The COVID-19 pandemic has a great impact on children's health. This study describes the characteristics of hospitalized children at the Instituto Nacional de Salud del Niño San Borja (INSN-SB) in Perú.


This was a retrospective study of patients with a confirmed diagnosis of COVID-19 from March to July 2020. Demographic, clinical, laboratory, radiological, and treatment information were collected. Data analysis included descriptive statistics and bivariate analysis to determine differences between patients in general wards and the Pediatric Intensive Care Unit (PICU).


We included 91 patients, 33 being females (36.3%). The most affected age group was children > 2 years of age (63 cases) with a median age of 6 years (IQR 3-10), and 61.5% were from Lima. The previous contact was determined in 30.8% of cases. A positive SARS CoV-2 PCR result was obtained in 50.6%. The presence of comorbidity was 53.8%. The most frequent symptoms were: fever (39.6%), general malaise (23.1%), cough (19.8%), and respiratory distress (14.3%). The presence of multisystem inflammatory syndrome in children (MIS-C) was confirmed in 6 patients. Antibiotics were administered in 76.9%. The most frequent radiological pattern was bilateral interstitial infiltrates (57.7%). Mortality was higher in patients in the ICU than in the hospitalization ward (27.3% vs. 4.3%, respectively; p = 0.020)


COVID-19 in children presents mild and moderate clinical manifestations. The presence of comorbidity is an important factor for hospitalization, and mortality is high upon admission to critical care units.

Keywords: Child; Comorbidity; Coronavirus Infections; Mortality. (fuente: MeSH NLM).


The coronavirus pandemic is the biggest public health crisis the world still has to face. It has been estimated that more than 90% of the cases correspond to the adult population and only between 1 to 5% occur in the pediatric population1, of which more than 90% are asymptomatic, mild, or moderate forms of presentation, and only 5.9 % severe cases2, this percentage is much lower compared to the 18.5% of severe cases reported in the adult population3.

The association between the presence of comorbidity and severe disease has been reported in a study of 48 pediatric patients admitted to the PICU, of which 40 children (83%) had some comorbidity4, in another study that included 651 children, 46% I present at least one comorbidity5.

The development of MIS-C has been described, which can be severe and present significant cardiac involvement6. Patients with MIS-C were found to have a 5-fold increased risk of being admitted to the PICU5. In Peru, the incidence of COVID-19 in adults will continue to be 13 times higher than in children7, however, the behavior of COVID-19 in pediatric patients with complex comorbidities has not been described.

The aim of this study is to describe the clinical, epidemiological, and treatment characteristics of children diagnosed with COVID-19 hospitalized at the INSN-SB, which is characterized as a highly complex specialized surgical center.


Design and study area

During the period from March 1 to July 31, 2020, a retrospective qualitative and quantitative observational study was carried out

Population and sample

For non-occasionally demonstrated convenience, all hospitalized patients under 18 years of age with a laboratory-confirmed diagnosis of COVID-19 who had the variables of interest were included (N=91). Consult the medical records of patients treated with COVID-19, the INSN-SB is a reference pediatric center with 306 beds. For the best care of patients with COVID-19, 24 beds were provided for patients with a confirmed case of COVID-19, 25 beds for patients with suspected COVID-19, and 12 beds for pediatric patients with PICU requirements.

Eligibility criteria: Patients with incomplete data were excluded and the clinical evaluation was performed by the pediatrician according to institutional care guidelines.

The definition of COVID-19 cases was considered according to the institutional standard of the Peruvian Ministry of Health (MINSA)8, as well as the definition of the MIS-C of the World Health Organization (WHO), which includes children and adolescents from 0 to 19 years old with fever greater than or equal to three days and other criteria9.

COVID-19 infection was diagnosed by the immunochromatographic blood test or by the polymerase chain reaction test of a nasopharyngeal swab, depending on their availability.

In addition, as part of the hospitalization criteria, confirmatory laboratory tests were performed on asymptomatic patients prior to the start of chemotherapy or in the preoperative period, the tests and images were indicated by the pediatrician and were performed according to institutional guidelines. (Figure 1)

Figure 1 

Study variables

The epidemiological variables evaluated were sex, age, origin by department, weight, height, comorbidity and direct contact with COVID-19 patients. The clinical variables included were: date of onset of symptoms and the presence or absence of symptoms such as malaise, cough, shortness of breath, diarrhea, abdominal pain, nausea, vomiting, headache, runny nose, and pharyngeal pain. The clinical signs considered were fever, conjunctival injection, rash, dyspnea, snoring, wheezing, crackles, sub-crackles, seizures, pharyngeal exudate, pretibial edema or scaling of extremities, and raspberry tongue.


Laboratory tests for SARS CoV-2 infection were both rapid and molecular tests. In addition, the following were included: hemoglobin, leukocytes, leukocyte differential, platelets, albumin, creatinine, ferritin, C-reactive protein, procalcitonin, sedimentation rate (ESR), lactate dehydrogenase (LDH), alanine aminotransferase (ALT), aspartate aminotransferase (AST) , total bilirubin, alkaline phosphatase, gamma-glutamyl transferase (GGT) prothrombin time (PT), D-dimer

Treatment received during COVID-19 infection is described based on drug groups (antibiotics, antifungals, antivirals, antiparasitics, anticoagulants, antipyretics, human immunoglobulin, corticosteroids, and vasoactive drugs)

Finally, the severity of the clinical picture, PICU requirement and admission date were evaluated, as well as the presence or absence of MIS-C; as well as, the hospital stays considering the final condition of the patient and the cut-off point as the last day of July 2020.

Statistical analysis.

The study data was collected and managed using the Integrated Hospital Management System (SIS Galen Plus)10and the REDCap electronic data capture tools11,12hosted at the INSN-SB.

A descriptive analysis was performed for the variables of interest; for quantitative variables due to an asymmetric distribution, medians and interquartile ranges (IQR) were analyzed, and for qualitative variables, frequency tables were analyzed.

The bivariate analysis was performed to identify the differences between the types of hospitalization (general wards and PICU), for qualitative variables the chi-square test and Fisher's test were used, while non-parametric tests were performed for numerical variables. Statistical analysis was performed with version 16 of the STATA program (StataCorp. 2019. Stata Statistical Software: Release 16. College Station, TX: StataCorp LLC). All differences were considered with a value of p < 0.05.

Ethical aspects

This study was approved by the Institutional Research Ethics Committee of the INSN-SB with project code PI-429.


Between March and July 2020, 576 patients were admitted to the INSN-SB with suspected COVID-19, of which 19.9% (n=115) had a diagnosis confirmed by molecular or rapid testing, a total of 91 were analyzed patients. The majority of patients were male, with the predominant age group being schoolchildren: 61.5% (n=56) of the patients came from the city of Lima and 89.1% (n=81) had incomplete vaccination, 100% from who (n=22) were admitted to the PICU. (Table 1)

Table 1.  Demographic characteristics of patients with COVID-19 seen at INSN SB (n=91). 

Characteristics Total
n %
  Female 33 36,3
  Male 58 63,7
Age (years) 4 (1-8)  
  Lima 56 61,5
  Provinces 35 38,5
Incomplete vaccination 81 89,1
Surgical admission    
  Emergency 21 53,8
  Elective 18 46,2
  Family 24 26,4
  Patient 4 4.4
  Unknown 63 69.2
Diagnostic test    
  Quick test 45 49,4
  Molecular test 46 50,6
  Normal 45 63,4
  Abnormal 26 36,6
Presence of comorbidity    
  Yes 49 53,8
  No 42 46,2
Presence of MIS-C
  Yes 6 6.6
  No 85 93.4
Patient's final condition
  Live 82 90.1
  Deceased 9 9.9

Regarding comorbidity, they occurred in 53.8% (n=49), of which 68.8% (n=15) were admitted to the ICU. In 31.2% (n=15) the most frequent comorbidity was neurological and 24.4% (n=12) cardiological, followed by 14.2% (n=7) hematological and 14.2% (n=7) oncological, finally in patients admitted to PICU, the most frequent comorbidity was cardiological 40% (n = 6) and neurological 20% (n = 3). (Table 2)

Table 2.  Comorbidities of patients with COVID-19 seen at INSN-SB (n=91). 

Comorbidities Total
N %
Presence of comorbidity    
  Yes 49 53,8
  No 42 46,2
Type of comorbidty    
  Neurological 15 31,2
  Cardiological 12 25,5
  Hematology 7 14,9
  Oncology 7 14,9
  Gastrointestinal 6 12,2
  Trauma 4 7,7
  Pneumology 4 7,7
  Burn 3 5,77
  Other 2 3,8

The symptoms reported were general malaise 23.1% (n=21), cough 19.8% (n=18), respiratory distress 14.3% (n=13), vomiting 12.1% (n=11); as evidenced signs fever 39.6% (n=36), dyspnea 13.2% (n=12), snoring 9.9% (n=9) and seizures 5.5% (n=5). (Table 3)

In general, the majority of patients had a normal chest X-ray 63.6% (n=14), with differences evidenced between children admitted to hospitalization wards and those admitted to PICU (74% vs 38%, respectively) or radiological pattern abnormal (26% vs 61.9%, respectively) (p < 0.01). In addition, the most frequent radiological pattern was bilateral interstitial infiltrates in 57.7% (n = 15). (Table 3)

Table 3.  Clincal and radiological characteristics of patients with COVID-19 seen at INSN-SB (n=91). 

Characteristics Total
n %
  General malaise 21 23,1
  Cough 18 19,8
  Respiratory distress 13 14,3
  Vomiting 11 11,2
  Abdominal pain 10 11,0
  Rhinorrhea 8 8,8
  Nausea 6 6,6
  Diarrhea 3 3,3
  Pharyngeal pain 3 3,3
  Seizures 2 2,2
  Headache 2 2,2
  Fever 36 39,6
  Dyspnea 12 13,2
  Snoring 9 9,9
  Sibilants 5 5,5
  Seizures 5 5,5
  Subcrepitant 4 4,4
  Adenopathies 4 4,4
  Rash 3 3,3
  Pretibial edema 2 2,2
  Raspberry tongue 1 1,1
  Conjunctival injection 1 1,1
Chest radiological pattern    
  Bilateral interstitial 15 57,7
  Unilateral Alveolar 8 30,7
  Unilateral interstitial 3 11,5
  Bilateral alveolar 2 7,6

Regarding mortality, differences were observed between children admitted to hospitalization wards and those admitted to PICU (4.3% vs 27.3%; p < 0.02). (Table 4).

Table 4.  Mortality reported in patients in hospital wards and PICU with COVID-19 attended at INSN-SB (n=22). 

Characteristics Hospitalization rooms PICU Total p value
Survival n=69 n=22 n=91  
  Yes 66 (95,6%) 16 (72,7%) 82 (90,1%)  
  No 3 (4,3%) 6 (27,3%) 9 (9%) 0.061

In relation to MIS-C, only 6.6% (n = 6) of the patients presented the criteria established by the WHO, most of these patients did not require PICU admission (n = 4).

In the patients who had laboratory tests on admission, we found that the main laboratory alteration was the levels of C-Reactive Protein (CRP) 9.4 mg/L (2.1 - 96.7) and D-Dimer 0.69 ug/ ml(0.27 - 1.65), we did not show greater alteration with respect to procalcitonin 0.14 (0.05-0.65) or in the values of TGP, AST and creatinine, with respect to the blood count the median of the hemoglobin was 11.8 g/dl (9.8 - 12.8), in addition we did not find leukocytosis, neutrophilia, left shift or marked lymphocytopenia (leukocytes at 10800x103/uL(7430 - 1450), lymphocytes 3040x103 /uL (1820-4910), neutrophils 5045x 103/uL (3095-9240) By IgM serology, Mycoplasma pneumoniae was the most isolated microorganism 9.9% (n=9), followed by Cytomegalovirus 3 .3% (n=3), Epstein Barr 2.2% (n=2) and Influenza 1.1% (n=1); gram-positive germs were isolated in 42.9% (n=9), in a smaller proportion were isolated Gram negative bacteria 38.1% (n=8) and fungi 19% (n=4) (Table 5).

Table 5.  Laboratorial and microbiological characteristics of patients with COVID-19 seen at INSN-SB. 

Characteristics Medium Interquartile range
  Hemoglobin 11,8 9,8-12,8
  Leukocytes 10800 7430-14570
  Lymphocytes 3040 1820-4910
  Monocytes 630 450-960
  Neutrophils 5045 3095-9240
  Rods 0 0,0
  Platelets 314000 233000-399500
  C-reactive protein 9,4 2,1-96,7
  ESR 28 15-50
  Creatinine 0,33 0,22-0,45
  Albumin 4,01 3,49-4,5
  AST 31 22-43
  GPT 17 13-32
  Ferritin 276,10 93,8-468,1
  Total Bilirubin 0,62 0,34-1,22
  Prothrombin time 14,8 13,7-16,2
  Fibrinogen 344,5 266-502
  D-dimer 0,69 0,27-1,65
  Procalcitonin 0,14 0,05-0,65
  CPK 110 40-254
  CPK-MB 29.9 24,5-38
  Lactate 2 1,4-3,4
  LDH 650 442-848
Microbiology n %
  Mycoplasma 9 9,9
  Cytomegalovirus 3 3,3
  Epstein Barr 2 2,2
  Influenza B 1 1,1
  Herpes 1 1 1,1
  Parvovirus B19 1 1,1
Type of insulation n=21 %
  Gram positive 9 42,9
  Gram negative 8 38,1
  Fungi 4 19,0

Regarding the drugs administered, 76.9% (n=70) of the patients received antibiotics, of which the ones with the highest prescription were cephalosporins in 58.6% (n=41) and glycopeptides in 40% ( n=28), it is also important to mention that 40% (n=25) patients received carbapenems and macrolides such as azithromycin were used in 17.1% (n=12). Antiparasitic were administered in 25.3% (n=23) of the patients, hydroxychloroquine in 17.4% (n=4). Antipyretics, mainly paracetamol, were used in 89% (n=81) patients, while 18.7 (n=17) received anticoagulants, 31.9% (n=29) corticosteroids, and 28.6 (n=26) vasoactive drugs. Regarding MIS-C, 5.5% (n=5) of patients received human immunoglobulin (Table 6).

Table 6.  Frequency of drug prescription in patients with COVID-19 seen at INSN SB (n=91). 

Medicines Total
n %
Antibiotics 70 76,9
  Cephalosporins 41 58,57
  Glycopeptides 28 40
  Carbapenems 25 35,71
  Penicillins + Beta lactamase inhibitors 14 20
  Macrolides 12 17,14
  Aminoglycosides 9 12,86
  Lincosamides 9 12,86
  Penicillins 8 11,43
  Sulfonamides 7 10
  Quinolones 3 4,29
  Oxazolidinones 1 1,43
  Nitrofurones 1 1,43
Antifungals 8 8,8
  Azoles 7 87,5
  Echinocandins 1 12,5
Antivirals 1 1,1
  Nucleotide analogues (Acyclovir) 1 100
Antiparasitics 23 25,3
  Nitroimidazoles 20 86,96
  4 amino-quinolines (Hydroxychloroquine) 4 17,39
  Benzimidazoles 1 4,35
Anticoagulants 17 18,7
  Low molecular weight heparin (Enoxaparin) 12 71


In this study, it was found that most of the patients presented a mild to moderate clinical picture, almost a third of the patients required admission to the PICU in the context of associated comorbidities. In addition, a group of patients with diagnostic criteria for MIS-C is described, all of whom evolved favorably.

Similar to what was reported in our study, according to the CDC, the median age of 576 hospitalized children was eight years13, with a predominance of males13,14. In addition, only a third of our patients had family contact (26.4%), unlike what was reported in other studies where they indicate a history of family contact in more than 40% of cases 14,15, this finding can be explained due to the lack of information about the diagnosis in the family environment.

Although in our study respiratory symptoms and fever were the most frequent clinical manifestations, 33% of patients presented gastrointestinal symptoms, in the literature the presentation of gastrointestinal manifestations is variable and is currently described in more than 20% of cases6,13,16. Similar to other studies, the most frequent coinfection was Mycoplasma pneumoniae and to a lesser extent with other respiratory viruses14,17,18. In this regard, it has been described that respiratory viral infections could predispose the development of super aggregated bacterial infections such as M. pneumoniae, due to altered respiratory mucociliary clearance and immune system response19; however, M. pneumoniae infection could also precede viral infection20.

Similar to what we reported, it was found that the most frequent comorbidities were neurological in 11% (65/614) and hematological-oncological in 8% (45/614)6. However, another study found comorbidity more asthma (12.3%), followed by sickle cell anemia (7%)21, many of these comorbidities are related to congenital pathologies, unlike in adults. According to severity, in our study it was reported that 68.2% of patients in the PICU presented comorbidities, being a high percentage as in another study that describes more than 80% of patients hospitalized in the PICU with comorbidities4

We observed an elevation of CRP and D-dimer, in accordance with what was found in the literature, a variety of laboratory alterations have been described in COVID-19, especially serum inflammatory markers6,15,22,23, One study found levels elevated CRP, procalcitonin, interleukin-6, ferritin, and D-dimer, in relation to severity(22). Our findings may be due to the higher proportion of patients with mild and moderate symptoms and because only the initial tests are included in the analysis.

In relation to the cases of MIS-C, in our study we found six patients with a diagnosis of MIS-C and two required PICU admission similar to that described in another Peruvian report (⅛)23, while in another study they found that MIS-C cases are 5 times more likely to be admitted to the PICU, however, no patient with MIS-C died6. In both studies, all progressed favorably. In contrast, a systematic review of MIS-C in children and adolescents reported that MIS-C appears to be a more severe condition with 68% (531/783) of cases requiring PICU admission24.

Antibiotic prescription was high despite having few microbiological findings. In the literature, a meta-analysis describes both in adults and children that 71.3% had a prescription for antibiotics, despite the fact that the prevalence of bacterial coinfections and COVID-19 was low and the frequency of secondary bacterial infection in patients was 14 ,3%26, these results suggest that antibiotics should be prescribed under a clear suspicion of bacterial infection in patients with COVID-19.

In our study, the use of hydroxychloroquine was rarely used and the use of immunoglobulin was reserved mainly for patients with MIS-C criteria, while in a systematic review 7.8% of children received hydroxychloroquine, 4.1% corticosteroids and 3 .1% immunoglobulin15Regarding hydroxychloroquine, the findings can be explained by the little scientific evidence initially reported on it, unlike intravenous immunoglobulin, which is accepted as immunomodulatory therapy in the management of Kawasaki disease and in the MIS-C6,23,26,27.

Our study has some limitations, such as presenting retrospective observational information, lack of complete baseline tests for COVID-19, partly explained by the diversity of clinical criteria for the request. Regarding the diagnosis of MIS-C, not all patients underwent a serological test for SARS-CoV 2, and only those with a positive confirmatory test were included in the present study.


In conclusion, SARS CoV-2 infection in children presents mild and moderate clinical manifestations. Finally, a group of patients presented comorbidities, this being greater in those admitted to the PICU and in those who died.


1. Ludvigsson JF. Systematic review of COVID-19 in children shows milder cases and a better prognosis than adults. Acta Paediatr [Internet]. 2020 [citado el 25 de marzo de 2022]; 109(6):1088-95. Disponible en: ]

2. Dong Y, Mo X, Hu Y, Qi X, Jiang F, Jiang Z, et al. Epidemiology of COVID-19 among children in China. Pediatrics [Internet]. 2020 [citado el 25 de marzo de 2022]; 145(6):e20200702. Disponible en: ]

3. Epidemiology Working Group for NCIP Epidemic Response, Chinese Center for Disease Control and Prevention. The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) in China. Zhonghua Liu Xing Bing Xue Za Zhi [Internet]. 2020 [citado el 25 de marzo de 2022]; 41(2):145-51. Disponible en: ]

4. Shekerdemian LS, Mahmood NR, Wolfe KK, Riggs BJ, Ross CE, McKiernan CA, et al. Characteristics and outcomes of children with Coronavirus disease 2019 (COVID-19) infection admitted to US and Canadian pediatric intensive care units. JAMA Pediatr [Internet]. 2020 [citado el 25 de marzo de 2022]; 174(9):868-73. Disponible en: ]

5. Jiang L, Tang K, Levin M, Irfan O, Morris SK, Wilson K, et al. COVID-19 and multisystem inflammatory syndrome in children and adolescents. Lancet Infect Dis [Internet]. 2020 [citado el 25 de marzo de 2022]; 20(11):e276-88. Disponible en: ]

6. Swann OV, Holden KA, Turtle L, Pollock L, Fairfield CJ, Drake TM, et al. Clinical characteristics of children and young people admitted to hospital with covid-19 in United Kingdom: prospective multicentre observational cohort study. BMJ [Internet]. 2020 [citado el 25 de marzo de 2022]; 370:m3249. Disponible en: ]

7. Ministerio de Salud del Perú. Situación actual: Brote de COVID-19 en Perú 2020. [citado el 25 de marzo de 2022]. Disponible en: ]

8. Centro Nacional de Epidemiología, Prevención y Control de Enfermedades. Ministerio de Salud del Perú. Alerta Epidemiológica Código: AE-019-2020 2020. Disponible en: [ Links ]

9. World Health Organization. Multisystem inflammatory syndrome in children and adolescents temporally related to COVID-19: Scientific Brief 2020. Disponible en: [ Links ]

10. Universidad Nacional Mayor de San Marcos. Gestión en Salud: SIS-GalenPlus 2020 Disponible en: [ Links ]

11. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform [Internet]. 2009 [citado el 25 de marzo de 2022]; 42(2):377-81. Disponible en: ]

12. Harris PA, Taylor R, Minor BL, Elliott V, Fernandez M, O'Neal L, et al. The REDCap consortium: Building an international community of software platform partners. J Biomed Inform [Internet]. 2019 [citado el 25 de marzo de 2022];95(103208):103208. Disponible en: ]

13. Kim L, Whitaker M, O'Halloran A, Kambhampati A, Chai SJ, Reingold A, et al. Hospitalization rates and characteristics of children aged <18 years hospitalized with laboratory-confirmed COVID-19 - COVID-NET, 14 states, March 1-July 25, 2020. MMWR Morb Mortal Wkly Rep [Internet]. 2020 [citado el 25 de marzo de 2022]; 69(32):1081-8. Disponible en: ]

14. Hoang A, Chorath K, Moreira A, Evans M, Burmeister-Morton F, Burmeister F, et al. COVID-19 in 7780 pediatric patients: A systematic review. EClinicalMedicine [Internet]. 2020 [citado el 25 de marzo de 2022]; 24(100433):100433. Disponible en: ]

15. Fang F, Luo XP. Facing the pandemic of 2019 novel coronavirus infections: the pediatric perspectives. Zhonghua Er Ke Za Zhi [Internet]. 2020 [citado el 25 de marzo de 2022]; 58(0):E001. Disponible en: ]

16. Götzinger F, Santiago-García B, Noguera-Julián A, Lanaspa M, Lancella L, Calò Carducci FI, et al. COVID-19 in children and adolescents in Europe: a multinational, multicentre cohort study. Lancet Child Adolesc Health [Internet]. 2020 [citado el 25 de marzo de 2022]; 4(9):653-61. Disponible en: ]

17. Zhang C, Gu J, Chen Q, Deng N, Li J, Huang L, et al. Clinical and epidemiological characteristics of pediatric SARS-CoV-2 infections in China: A multicenter case series. PLoS Med [Internet]. 2020; 17(6):e1003130. Disponible en: ]

18. Wu Q, Xing Y, Shi L, Li W, Gao Y, Pan S, et al. Coinfection and other clinical characteristics of COVID-19 in children. Pediatrics [Internet]. 2020 [citado el 25 de marzo de 2022]; 146(1):e20200961. Disponible en: ]

19. Morris DE, Cleary DW, Clarke SC. Secondary bacterial infections associated with influenza pandemics. Front Microbiol [Internet]. 2017; 8:1041. Disponible en: [ Links ]

20. Chiu C-Y, Chen C-J, Wong K-S, Tsai M-H, Chiu C-H, Huang Y-C. Impact of bacterial and viral coinfection on mycoplasmal pneumonia in childhood community-acquired pneumonia. J Microbiol Immunol Infect [Internet]. 2015 [citado el 25 de marzo de 2022]; 48(1):51-6. Disponible en: ]

21. Foster CE, Moulton EA, Munoz FM, Hulten KG, Versalovic J, Dunn J, et al. Coronavirus disease 2019 in children cared for at Texas children's hospital: Initial clinical characteristics and outcomes. J Pediatric Infect Dis Soc [Internet]. 2020 [citado el 25 de marzo de 2022]; 9(3):373-7. Disponible en: ]

22. Zachariah P, Johnson CL, Halabi KC, Ahn D, Sen AI, Fischer A, et al. Epidemiology, clinical features, and disease severity in patients with Coronavirus disease 2019 (COVID-19) in a children's hospital in New York City, New York. JAMA Pediatr [Internet]. 2020 [citado el 5 de abril de 2022]; 174(10):e202430. Disponible en: ]

23. Coll-Vela LED, Zamudio-Aquise MK, Nuñez-Paucar H, Bernal-Mancilla RR, Schult-Montoya SC, Ccorahua-De La Paz M, et al. Síndrome inflamatorio multisistémico asociado a COVID-19 en niños: serie de casos en un hospital pediátrico de Perú. Rev Peru Med Exp Salud Pública [Internet]. 2020 [citado el 5 de abril de 2022]; 37(3):559-65. Disponible en: ]

24. Radia T, Williams N, Agrawal P, Harman K, Weale J, Cook J, et al. Multi-system inflammatory syndrome in children & adolescents (MIS-C): A systematic review of clinical features and presentation. Paediatr Respir Rev [Internet]. 2021 [citado el 5 de abril de 2022];38:51-7. Disponible en: ]

25. Langford BJ, So M, Raybardhan S, Leung V, Westwood D, MacFadden DR, et al. Bacterial co-infection and secondary infection in patients with COVID-19: a living rapid review and meta-analysis. Clin Microbiol Infect [Internet]. 2020 [citado el 5 de abril de 2022]; 26(12):1622-9. Disponible en: ]

26. Newburger JW, Takahashi M, Gerber MA, Gewitz MH, Tani LY, Burns JC, et al. Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association: A statement for health professionals from the committee on rheumatic fever, endocarditis and Kawasaki disease, council on cardiovascular disease in the young, American Heart Association. Circulation [Internet]. 2004 [citado el 5 de Abril de 2022];110(17):2747-71. Disponible en: ]

27. Pouletty M, Borocco C, Ouldali N, Caseris M, Basmaci R, Lachaume N, et al. Paediatric multisystem inflammatory syndrome temporally associated with SARS-CoV-2 mimicking Kawasaki disease (Kawa-COVID-19): a multicentre cohort. Ann Rheum Dis [Internet]. 2020 [citado el 5 de abril de 2022]; 79(8):999-1006. Disponible en: ]

Funding sources: self-financing.

8Article published by the Journal of the faculty of Human Medicine of the Ricardo Palma University. It is an open access article, distributed under the terms of the Creatvie Commons license: Creative Commons Attribution 4.0 International, CC BY 4.0(, that allows non-commercial use, distribution and reproduction in any medium, provided that the original work is duly cited. For commercial use, please contact

Received: July 01, 2022; Accepted: August 19, 2022

Correspondence: Christian Manuel Chiara Chilet. Address: Av. Agustin de la Rosa Toro 1399 - San Borja. Telephone number: (511) 230 0600

Authorship contributions: C.Ch., M.L, J.M., B.S., D.P., R.P., F.M., A.M, and J.W.L planned the study. C.Ch., M.L, J.M., B.S., D.P., R.P., J.B., M.S. and J.W.L collected the data. C.Ch., J.W.L and M.L. performed the statistical analysis and the generation of figures. All authors reviewed the manuscript.

Conflicts of interest: The authors declare no conflict of interest.

Creative Commons License Este es un artículo publicado en acceso abierto bajo una licencia Creative Commons